105 related articles for article (PubMed ID: 32000051)
1. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties.
Incerti M; Russo S; Corrado M; Giorgio C; Ballabeni V; Chiodelli P; Rusnati M; Scalvini L; Callegari D; Castelli R; Vacondio F; Ferlenghi F; Tognolini M; Lodola A
Eur J Med Chem; 2020 Mar; 189():112083. PubMed ID: 32000051
[TBL] [Abstract][Full Text] [Related]
2. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
[TBL] [Abstract][Full Text] [Related]
3. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor.
Incerti M; Russo S; Callegari D; Pala D; Giorgio C; Zanotti I; Barocelli E; Vicini P; Vacondio F; Rivara S; Castelli R; Tognolini M; Lodola A
J Med Chem; 2017 Jan; 60(2):787-796. PubMed ID: 28005388
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
6. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
7. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
Dobrzanski P; Hunter K; Jones-Bolin S; Chang H; Robinson C; Pritchard S; Zhao H; Ruggeri B
Cancer Res; 2004 Feb; 64(3):910-9. PubMed ID: 14871820
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of ester-linked lithocholic acid dimers.
Nahar L; Turner AB
Steroids; 2003 Dec; 68(14):1157-61. PubMed ID: 14643877
[TBL] [Abstract][Full Text] [Related]
10. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
12. 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors.
Lim CJ; Oh KS; Ha JD; Lee JH; Seo HW; Chae CH; Kim DG; Lee MJ; Lee BH
Bioorg Med Chem Lett; 2014 Sep; 24(17):4080-3. PubMed ID: 25124116
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
[TBL] [Abstract][Full Text] [Related]
15. Chemical Synthesis of Rare Natural Bile Acids: 11α-Hydroxy Derivatives of Lithocholic and Chenodeoxycholic Acids.
Namegawa K; Iida K; Omura K; Ogawa S; Hofmann AF; Iida T
Lipids; 2018 Apr; 53(4):403-411. PubMed ID: 29520792
[TBL] [Abstract][Full Text] [Related]
16. Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor.
Jannu AK; Puppala ER; Gawali B; Syamprasad NP; Alexander A; Marepally S; Chella N; Gangasani JK; Naidu VGM
Int J Pharm; 2021 Aug; 605():120819. PubMed ID: 34166727
[TBL] [Abstract][Full Text] [Related]
17. Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
Heinzlmeir S; Kudlinzki D; Sreeramulu S; Klaeger S; Gande SL; Linhard V; Wilhelm M; Qiao H; Helm D; Ruprecht B; Saxena K; Médard G; Schwalbe H; Kuster B
ACS Chem Biol; 2016 Dec; 11(12):3400-3411. PubMed ID: 27768280
[TBL] [Abstract][Full Text] [Related]
18. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
Giorgio C; Mena P; Del Rio D; Brighenti F; Barocelli E; Hassan-Mohamed I; Callegari D; Lodola A; Tognolini M
Mol Nutr Food Res; 2015 Nov; 59(11):2155-67. PubMed ID: 26307544
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic activity of 4'-thio-beta-D-arabinofuranosylcytosine.
Roy AM; Tiwari KN; Parker WB; Secrist JA; Li R; Qu Z
Mol Cancer Ther; 2006 Sep; 5(9):2218-24. PubMed ID: 16985055
[TBL] [Abstract][Full Text] [Related]
20. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A
J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
